Candice Roth, MSN, RN, CENP, Describes the Evolution of Electronic Treatment Pathways at Levine Cancer Institute

Video

Candice Roth, MSN, RN, CENP, spoke about how the electronic treatment pathways have evolved over time.

At the Association of Community Cancer Centers 48th Annual Meeting and Cancer Center Business Summit, CancerNetwork® spoke with Candice Roth, MSN, RN, CENP, assistant vice president at Levine Cancer Institute in Charlotte, North Carolina, about how measuring success of electronic treatment pathways has evolved from counting the number of clicks to specifically pinpointing how clinicians are using the platform.

Transcript:

First and foremost, it was a new platform several years ago, so just getting providers to use it compared with the way they previously practiced [was difficult]. It was [simply about] just counting the number of clicks initially in terms of metrics. [We were focused on making] sure that our providers were aware that they needed to use this platform and or that it was available for their use. Similarly, any of our nurses can do the same.

In terms of metrics, initially it was very much about how many clicks we had. Then as we progressed, we’ve been able to track clinical trial touchpoint eligibility for patients. We also look at ensuring that we are being consistent and standard by way of how we treat breast cancer, for example. We have all those metrics and all of the behind the scenes [information] that we monitor and present by way of dashboards to all of our providers.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.